Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic ductal adenocarcinomas (PDACs) are often hypovascular, leading to increased hypoxia inducible factor 1 alpha (HIF1A).
• HIF1A is known to promote cancer cell survival under low-oxygen conditions.

Purpose of the Study:

• To investigate the role of HIF1A in pancreatic tumor development and progression in mice.
• To understand the molecular mechanisms by which HIF1A influences pancreatic cancer metastasis.

Main Methods:

• Utilized genetically engineered mouse models (KPC, EKPC) with and without pancreas-specific HIF1A depletion.
• Performed histological and immunohistochemical analyses of pancreatic tissues.
• Conducted in vitro assays (migration, invasion, immunoblots, qPCR, LC-MS) and in vivo metastasis models using human pancreatic cancer cell lines.
• Analyzed The Cancer Genome Atlas (TCGA) data for human PDAC tumors.

Main Results:

• Pancreas-specific deletion of HIF1A in mice led to more advanced PDACs, increased invasion and metastasis, and reduced survival.
• HIF1A-deficient pancreatic cancer cells exhibited higher invasive and metastatic potential.
• HIF1A-knockout cells showed increased expression of PPP1R1B, which correlated inversely with HIF1A levels in human PDAC.
• Higher PPP1R1B levels and lower HIF1A levels were observed in metastatic human cell lines, and PPP1R1B knockdown reduced metastasis.
• PPP1R1B promoted p53 degradation by stabilizing MDM2 phosphorylation.

Conclusions:

• HIF1A functions as a tumor suppressor in pancreatic cancer by inhibiting PPP1R1B expression and subsequent p53 degradation.
• Loss of HIF1A enhances the invasive and metastatic capabilities of pancreatic cancer cells.